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Chromatin remodeling and histone modification are essential for eukaryotic transcription regulation, but
little is known about chromatin-modifying activities acting on RNA polymerase III (Pol III)-transcribed genes.
The human U6 small nuclear RNA promoter, located 5 of the transcription start site, consists of a core region
directing basal transcription and an activating region that recruits the transcription factors Oct-1 and Staf
(ZNF143). Oct-1 activates transcription in part by helping recruit core binding factors, but nothing is known
about the mechanisms of transcription activation by Staf. We show that Staf activates U6 transcription from
a preassembled chromatin template in vitro and associates with several proteins linked to chromatin modi-
fication, among them chromodomain-helicase-DNA binding protein 8 (CHD8). CHD8 binds to histone H3 di-
and trimethylated on lysine 4. It resides on the human U6 promoter as well as the mRNA IRF3 promoter in
vivo and contributes to efficient transcription from both these promoters. Thus, Pol III transcription from type
3 promoters uses some of the same factors used for chromatin remodeling at Pol II promoters.
The state of chromatin packaging defines in large part the
transcriptional competency of genes transcribed by RNA poly-
merases (Pol) I and II. In this process, it is clear that the
packaging of DNA into certain chromatin states has a repres-
sive effect on transcription, in particular on the initiation and
elongation steps, as histone octamers within nucleosomes can
block the binding of transcription initiation factors and hamper
the progress of RNA Pol along a gene (24, 40, 48, 79). For
transcription to take place, the chromatin template needs to be
modified such that the accessibility of transcription factors to
their promoter targets is increased and transcription elonga-
tion is facilitated (36, 74).
Chromatin modification at Pol II genes is accomplished by a
large number of factors (47) that are recruited to chromatin
through contacts with (i) histones with various modifications in
their N-terminal regions, (ii) the DNA, and (iii) certain acti-
vators. Such activators can bind to chromatin templates and
recruit chromatin-modifying factors, which then remodel nu-
cleosomes or modify histones (11, 23). Successive waves of
chromatin modifications are thought to allow for the regulated
assembly of transcription initiation complexes, leading to ac-
tive transcription.
Much less is known about the requirements for chromatin
modification at Pol III-transcribed genes. Pol III, like Sp6 Pol,
is capable of transcribing through a nucleosome on a mono-
nucleosomal template, causing an intranucleosomal loop fol-
lowed by transfer of the histone octamer to a different position
of the same template (62, 63). This shows that Pol III can
transcribe through a single nucleosome without the help of
chromatin-modifying activities. However, a large number of
observations suggests that the initiation step of Pol III tran-
scription, as well as elongation through more than a single
nucleosome, is influenced by chromatin-modifying activities.
For example, transcription of an Alu element in vitro is pro-
foundly repressed by packaging of the template into nucleo-
somes (10), and histone acetylation dramatically enhances
transcription by Pol III through dinucleosomal templates as
well as nucleosomal arrays (68, 69). Moreover, nucleosome
depletion in vivo activates Pol III transcription at certain nor-
mally repressed Pol III promoters in the Saccharomyces cerevi-
siae (yeast) genome (16), and in the case of the yeast U6
snRNA gene, binding of the transcription factors IIIC and IIIB
is accompanied by changes in nucleosome position (56). Such
observations are consistent with the proposal that chromatin
modification, either histone modification or chromatin remod-
eling or both, is indeed required. However, which factors are
involved and what role, if any, is played by chromatin-remod-
eling factors acting on Pol III-transcribed genes are so far
largely undocumented.
The human U6 small nuclear RNA (snRNA) promoter is a
type 3 Pol III promoter, i.e., it is located in the 5 flanking
sequence of the gene and contains two elements required for
basal transcription in vitro, a TATA box and a proximal se-
quence element (PSE), as well as a distal sequence element
(DSE) that enhances transcription from the basal promoter
(17). The U6 promoter and all type 3 Pol III promoters are
very similar to the Pol II promoters of snRNA genes, which
also contain a DSE and a PSE but lack the TATA box (17).
The DSEs of both type 3 Pol III promoters and Pol II
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snRNA promoters generally contain an octamer sequence,
which recruits Oct-1, and an SPH (for Sph1 postoctamer ho-
mology) sequence, which recruits a transcription factor called
selenocysteine tRNA-activating factor (Staf) (52) or SPH bind-
ing factor (17, 45). Oct-1 activates transcription both through
its POU (Pit-1, oct-1, unc86) DNA binding domain, which,
thanks to a positioned nucleosome, contacts the PSE binding
factor SNAPc and helps its recruitment, and through its acti-
vation domains (78). Staf was cloned first from Xenopus laevis,
but two human proteins, ZNF143 and, to a lesser extent,
ZNF76, are similar to Xenopus Staf, share similar DNA bind-
ing specificities, and can activate Pol II and III snRNA gene
transcription (35). How the activation domains of Oct-1 and
Staf activate transcription from DSE-containing promoters is
unknown, but by analogy to activators of mRNA-encoding Pol
II genes, it seems probable that the mechanism involves the
modification of chromatin.
Among the large number of chromatin-binding proteins
identified in recent years are the chromodomain-helicase-DNA
binding, or CHD, proteins. These highly conserved but poorly
understood proteins are characterized by two tandem chromo-
domains in their N terminus followed by an SNF2-like helicase
domain. In mammalian cells, there are nine CHD proteins,
which can be divided into three subfamilies according to se-
quence similarities (53). Subfamily I contains CHD1 and
CHD2, subfamily II contains CHD3 to CHD5, and subfamily
III contains CHD6 to CHD9. To date, the best-characterized
CHDs are CHD1 and CHD3/CHD4. CHD1 and CHD2 con-
tain a DNA binding domain with an AT hook (2). CHD1 can
assemble chromatin in vitro (29, 46) and remodel nucleosomes
(67). It associates with NCoR and histone deacetylases as well
as with RNA splicing proteins, linking it to transcription re-
pression and pre-mRNA splicing, respectively (65). CHD1 also
associates with the transcription elongation machinery (25, 58)
and is concentrated in actively transcribed areas, suggesting
that it is involved in Pol II transcription activation, probably at
the transcription elongation step. Indeed, the double chromo-
domain of human CHD1 interacts with histone H3 di- or
trimethylated at lysine 4, a marker of active chromatin (13, 59).
The subfamily II CHD3 (Mi2a) and CHD4 (Mi2b) proteins
are closely related and characterized by two PHD (plant ho-
meodomain) zinc fingers (3, 15) located N terminal of the
double chromodomain. They are in complexes containing
the histone deacetylases HDAC1/HDAC2 and referred to as the
Mi2 (71), NuRD (nucleosome-remodeling histone deacety-
lase) (76, 77), and NRD (nucleosome remodeling and deacety-
lating) (66) complexes. These complexes can remodel chroma-
tin to facilitate access of deacetylases and repress transcription
(72). CHD4 is, however, also implicated in transcription acti-
vation because it associates with BRG1, a subunit of the SWI/
SNF complex, as well as with a complex of nucleolar proteins
containing UBF, MCRS1 (microspherule protein 1), and RFP
(RET finger protein) implicated in activation of rRNA gene
transcription by Pol I (55). Mouse CHD5 has recently been
shown to correspond to a tumor suppressor controlling cell
proliferation and apoptosis (4).
The subfamily III members contain three conserved motifs
called CR1 through CR3, as well as a SANT domain (1), two
BRK domains, and a slightly divergent AT hook DNA binding
domain, all located C terminal of the helicase domain. Human
chromodomain helicase DNA binding protein 8 (CHD8) co-
purifies with the MLL1-WDR5 complex (8), and mouse CHD8
has recently been shown to interact with CTCF through its
BRK domains and to be involved in CTCF-dependent insula-
tor function, as its down-regulation by RNA interference
(RNAi) reduced the insulator activity of the H19 DMR (dif-
ferentially methylated region) insulator (19).
Here, we have explored the role of human Staf (hStaf;
ZNF143) in transcription from the human U6 snRNA gene.
We found that hStaf activates transcription from a U6 gene
template assembled into chromatin and further identified
CHD8 as an hStaf-associated protein required for efficient U6
transcription in vivo, as well as for transcription of the IRF3
gene, a Pol II-transcribed gene. These results show that a
function of CHD8 is in activation of transcription from type 3
Pol III promoters. This in turn suggests that transcription of
Pol III genes requires chromatin modification and that at least
in the case of type 3 Pol III promoters, some of the factors used
are also involved in chromatin remodeling of Pol II promoters.
MATERIALS AND METHODS
GST-hStaf expression and purification. Glutathione S-transferase (GST)-
hStaf was expressed in Escherichia coli BL21 with the T7 expression system (61)
from a pSBet vector expressing hStaf tagged with GST followed by a TEV site at
the N terminus and six histidines at the C terminus.
Chromatin assembly, MNase footprinting, and in vitro transcription from the
chromatin template. The S-190 extract was prepared and the template assembled
into chromatin as described previously (78). Recombinant hStaf was added to a
concentration of 90 nM at the end of the chromatin assembly reaction. The
quality of the chromatin template was checked by micrococcal nuclease (MNase)
digestion. MNase footprinting was performed by linear PCR as described in
reference 78. For transcription assays 10 l of chromatin template with or
without added hStaf was mixed with 15 l of HeLa whole-cell extract from which
endogenous hStaf had been previously depleted by incubation with anti-hStaf
antibody beads in a final volume of 40 l containing 25 mM HEPES-KOH, pH
7.9, 60 mM KCl, 10 ng/ml of poly(dG-dC)  poly(dG-dC) (GE Healthcare), 5
mM MgCl2, 1 mM EGTA, 5 mM spermidine, 4 mM dithiothreitol (DTT), 2 mM
each of ATP, GTP, CTP, and UTP, and 2 ng of recombinant TATA box-binding
protein. The reaction mixture was incubated at 30°C for 1 h, and RNA was
analyzed as described previously (78).
ChIPs. The chromatin immunoprecipitation (ChIP) protocol was adapted
from that described in reference 78. HeLa cells were fixed with 1% formalde-
hyde. After nucleus lysis, chromatin was sonicated for 8 min with a Bioruptor
(Diagenode) with intervals of 30 seconds on and 30 seconds off. For each ChIP
sample, 600 l of chromatin and 1 g of antibody were mixed and incubated
overnight at 4°C. Six microliters of protein G magnetic beads was then added to
capture DNA/protein/antibody complexes. After being extensively washed, the
DNA/protein/antibody complexes were eluted twice with 150 l of elution buffer
(50 mM NaHCO3, 1% sodium dodecyl sulfate [SDS]). The supernatant was
collected and incubated at 67°C for 5 h to reverse the formaldehyde cross-linking,
and the nucleic acids were precipitated and analyzed by PCR. The primers used
for PCR were located in the proximal (U6-4U [5TTCTTGGGTAGTTTGCAG
3] and U6-2L [5 GTTTCGTCCTTTCCACAAG 3]) region of the U6-1 active
promoter, in the promoter region (U64-1 and U64-120 [see reference 7]) of the
inactive U6-4 promoter, or in the U1 promoter region (U1-4UP [5CACGAA
GGAGTTCCCGTG3] and U1-2L [5CCCTGCCAGGTAAGTATG3]) as in-
dicated in the figure legends. For the PCRs, serial dilutions were performed in
test experiments to establish conditions giving rise to linear response.
Identification of hStaf-associated proteins. The GST pull-down experiment
was carried out according to the procedure described in reference 27. Briefly, 200
g of GST fusion protein-coupled glutathione beads prepared as described
above were equilibrated with buffer D200 (50 mM HEPES-KOH, pH 7.9, 200
mM KCl, 20% glycerol, 0.5 mM EDTA, 5 mM MgCl2, 1 mM DTT). Nuclear
HeLa cell extracts (6) from 1  109 HeLa cells were diluted 1:2 with D200 buffer
and incubated with glutathione beads coupled to fusion proteins for 3 h at 4°C.
After the incubation, the beads were washed extensively with K200 buffer (D200
buffer without glycerol) before elution with 2 column volumes of T300 buffer (50
mM HEPES-KOH, pH 7.9, 300 mM KCl, 0.5 mM EDTA, 5 mM MgCl2, 1 mM
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DTT, 0.05% Tween 20) followed by 2 column volumes of T600 buffer (50 mM
HEPES-KOH, pH 7.9, 600 mM KCl, 0.5 mM EDTA, 5 mM MgCl2, 1 mM DTT,
0.05% Tween 20). The eluted proteins were trichloroacetic acid (TCA) precip-
itated for MudPIT analysis. TCA-precipitated proteins were denatured with
urea, reduced, alkylated, and digested with endoproteinase Lys-C (Roche) fol-
lowed by modified trypsin (Roche) as described in reference 73. Peptide mixtures
were pressure loaded onto 100 m fused silica microcapillary columns packed
with 5 m C18 reverse phase (Aqua; Phenomenex), strong cation-exchange
particles (Partisphere SCX; Whatman), and reverse phase (30). Loaded micro-
capillary columns were placed in-line with a Quaternary Agilent 1100 series
high-performance liquid chromatography pump and a Deca-XP ion trap mass
spectrometer equipped with a nano-liquid chromatography electrospray ioniza-
tion source (ThermoFinnigan). Fully automated six-step MudPIT runs were
carried out, as described in reference 14. Tandem mass spectra were searched
with SEQUEST (9) against a database of 60,238 amino acid sequences, consist-
ing of 34,180 human proteins (NCBI 2006-09-05 release), 177 usual contami-
nants (such as human keratins, immunoglobulin G, and proteolytic enzymes),
126 epitope-tagged proteins, and, to estimate false-discovery rates, 30,119 ran-
domized amino acid sequences derived from each nonredundant protein entry.
Spectrum/peptide matches were retained only if they had a normalized difference
in cross-correlation scores of at least 0.08, and minimum cross-correlation score
of 1.8 for singly charged spectra, 2.5 for doubly charged spectra, and 3.5 for triply
charged spectra. In addition, peptides had to be fully tryptic and at least seven
amino acids long. Peptide hits from multiple runs were compared using
CONTRAST (64) and contrast-report (14). A further criterion for consideration
was that proteins had to be detected by at least two such peptides in all combined
runs. Under this set of criteria, no false-positive “shuffled” proteins were de-
tected (false-discovery rate  0). Spectral counts were normalized as described
in reference 80 to calculate normalized spectral abundance factors, parameters
used to estimate relative protein levels.
Co-IPs. Antibodies against hStaf and CHD8 were cross-linked to protein G
agarose beads (Roche) with dimethyl pimelimidate (Sigma). The antibody
against hStaf (antibody 19164) was raised against peptide RIASRIQQGETPG
LDD, which is present in ZNF143 but not in ZNF76. The antibodies against
CHD8 were raised against peptide DSLTDDSFNQVTQDPIEE (antibody
19224) or peptide SQGYDSSERDFSLIDDPM (antibody 19225). For coimmu-
noprecipitations (co-IPs), HeLa nuclear extracts (200 g protein) were incu-
bated with 100 l of protein G beads with cross-linked antibody for 3 h at 4°C.
The beads were washed extensively with K300 buffer, and the immunoprecipi-
tated proteins were released by the addition of 100 l of 2 Laemmli buffer and
boiling for 5 min. The eluted proteins were resolved by SDS-polyacrylamide gel
electrophoresis (PAGE) and analyzed by immunoblotting.
Reporter cell line construction. To establish the IMR90-C2.5 clonal cell line
expressing a U6 promoter-directed unstable RNA, IMR-90Tert cells were trans-
fected by the calcium phosphate method with 5 g of pU6/RA.2U6end-Dsred,
a derivative of pDsRed-Express-DR (Clontech) with an insert consisting of the
human U6 promoter followed by a piece of -globin gene cloned in the reverse
orientation as in pU6/Hae/RA.2 (28), followed by the 3 end of the U6 gene and
3 flanking sequences. The cells were split 48 h later and kept under G418
selection (500 g/ml) for 21 days. Individual clones were expanded and tested for
expression of the U6 construct.
Protein knock-down with RNAi and RT-PCR. RNAi oligonucleotides were
transfected into IMR90-C2.5 cells with Hi-Perfect transfection reagent
(QIAGEN). The cells were collected 24 h after the last of three rounds of trans-
fections performed at 24-h intervals. Total RNA was isolated with miRNeasy
mini kit (QIAGEN). One microgram of total RNA was used for first-strand
DNA synthesis with TaqMan reverse transcription (RT) reagents (Applied Bio-
systems), and the resulting cDNA was used as the starting material for PCRs. For
the PCRs, we first diluted the PCR templates 1:10, 1:50, and 1:250 to determine,
for each primer pair, the highest template concentration that still gave a signal in
the linear range. These concentrations were used for subsequent experiments.
The intensity of the PCR bands was measured with an Alpha imager (Alphain-
notech).
CHD8 interaction with histone peptides. The protocol of CHD8 interaction
with histone peptides was adapted from reference 43. hStaf-associated proteins
were eluted with 600 mM KCl as described above, dialyzed against buffer D150T
(10% glycerol, 20 mM HEPES-KOH, pH 7.9, 150 mM KCl, 0.5 mM EDTA,
0.05% Tween 20), and incubated with 2 g of different biotinylated histone H3
peptides for 2 h at 4°C. The peptides were purchased either from Upstate
Biotechnology or from the Tufts University peptide synthesis facility. At the end
of the incubation, 20 l of streptavidin beads was added to each sample, and the
sample was incubated at 4°C for 2 h. The beads were washed and the bound
proteins eluted by Laemmli buffer and boiling. The samples were analyzed by
SDS-PAGE and immunoblotting with anti-CHD8 and anti-hIno80 antibodies.
Antibodies for hStaf, CHD8, and hIno80 were produced by Custom Hybridoma.
RESULTS
hStaf activates U6 transcription from a chromatin template.
To explore the role of hStaf in transcription from the human
U6 gene, we first tested for the presence of this protein on the
human U6 promoter by ChIP. Exponentially growing HeLa
cells were treated with formaldehyde to cross-link protein com-
plexes to DNA, and chromatin was extracted, sonicated, and
used for IPs with an anti-hStaf antibody. Anti-Brf2 and anti-
TFIIB antibodies were used as positive and negative controls,
respectively, and a sample mock immunoprecipitated without
antibody was also included. The PCR was carried out with two
sets of primers, one specific for the promoter region of the U6
gene we worked with (test primers; U6-1 gene) and the other
specific for the 5 flanking region of one of the pseudo-U6 genes
(control primers; U6-4 gene) (7). The top panel of Fig. 1A
shows the linearity of the PCR with a titration of the input
material, and the bottom panel shows the results obtained with
the various antibodies. hStaf was present on the human U6
gene but not the pseudo-U6 gene (Fig. 1A, bottom panel, lanes
5 and 6). As expected, so was Brf2, whereas TFIIB was absent
from both the gene and pseudogene (lanes 7 to 10).
Next, we tested the binding of hStaf to a U6 template pre-
assembled into chromatin in vitro. The U6 template was pre-
assembled with Drosophila melanogaster S190 extract, as de-
scribed before (78). hStaf was then added to the chromatin
template, and binding was visualized by partial micrococcal
nuclease digestion followed by linear PCR with an end-labeled
primer, as described before (see reference 78). As shown in
Fig. 1B, the pattern obtained with naked DNA was different
from that obtained with chromatin-assembled DNA, as ex-
pected (compare lanes 1 and 2). Upon the addition of hStaf, a
clear footprint over the hStaf binding site (SPH sequence) was
obtained (lane 3). To confirm that the footprint corresponded
to binding to preassembled chromatin rather than to naked
DNA, we tested the effect of apyrase addition. As shown in Fig.
1B, right panel, the addition of apyrase obliterated the foot-
print, indicating that it is ATP dependent (compare lanes 5 and
7). Since hStaf is not known to require ATP to bind to naked
DNA (see, for example, reference 45), the ATP requirement
suggests that hStaf is indeed binding to preassembled chroma-
tin and requires the help of an ATP-dependent chromatin-
modifying activity to do so.
We then tested the transcriptional activity of such a tem-
plate. The addition of recombinant hStaf to the preassembled
chromatin template before the start of the transcription assay
activated U6 transcription (Fig. 1C, lanes 1 and 2), and this was
dependent on an intact SPH sequence (compare lanes 2 and 4;
note that lanes 1, 2, 3, and 4 are from the same gel). As
observed before (45), the addition of purified recombinant
hStaf to a HeLa cell extract also activated U6 transcription
from a naked DNA template in an SPH sequence-dependent
manner, although in our hands, this activation was rather weak
(lanes 5 to 8). Thus, like many transcription factors, including
chimeric proteins containing the VP16 activation domain (see,
for example, reference 37), hStaf can activate transcription
from both naked (45) and chromatinized template. Together,
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the results indicate that hStaf is capable of binding to its target
site in a chromatinized U6 template and may activate tran-
scription at least in part by recruiting histone-modifying or
chromatin-remodeling factors.
Identification of hStaf-associating proteins. Xenopus Staf
can be divided into three major regions: a transcription acti-
vation domain, a zinc finger domain, and a C-terminal domain
with no known function (51). The activation domain contains a
region required for activation of snRNA-type genes and an-
other region composed of four imperfect tandem repeats re-
quired for the activation of mRNA-encoding Pol II genes (51).
The zinc finger domain contains seven zinc fingers of the C2-H2
type, different sets of which can be used to bind to different
DNA targets (49). These regions are conserved in human Staf,
as illustrated in Fig. 2A.
To understand how hStaf activates U6 transcription, we set
out to identify hStaf-associated proteins by conducting pull-
down experiments with full-length hStaf as well as versions of
hStaf lacking C-terminal (hStafC) or N-terminal (hStafN)
sequences, all fused to GST (Fig. 2A). We used Nef, a human
immunodeficiency virus type 1 protein localized in the cyto-
plasm, fused to GST, as a negative control. The GST fusion
proteins expressed in E. coli and coupled to glutathione aga-
rose beads were incubated with HeLa nuclear extracts, and
proteins retained on the beads were sequentially eluted with
300 and 600 mM KCl and precipitated with TCA for MudPIT
analysis.
A total of 289 nonredundant proteins were identified by at
least two peptide hits. After elimination of the proteins also
pulled down by GST-Nef and the usual contaminants, 230
remained. Since the N-terminal domain of hStaf contains the
transcription activation domains (Fig. 2A), we further elimi-
nated 190 proteins that were pulled down by hStafN, which
lacks these N-terminal sequences, as well as the proteins pulled
down by full-length hStaf but not by hStafC. Twenty-five
proteins that were pulled down either by both full-length hStaf
and hStafC (13 proteins) or just by hStafC (12 proteins)
remained. The merged list of these 25 proteins, which are
likely to associate with the hStaf sequences uniquely present in
hStafC, i.e., sequences located N terminal of the zinc finger
domain (Fig. 2A), is shown in Fig. 2B, with the proteins iden-
tified only in the hStafC pull-down experiment indicated.
Many of these proteins are involved or likely to be involved in
chromatin modification (see Discussion). The protein with the
FIG. 1. hStaf activates U6 transcription from a chromatin tem-
plate. (A) ChIP of hStaf on the U6-1 promoter. Rapidly growing HeLa
cells were treated with formaldehyde, and cross-linked chromatin was
extracted, sonicated, and used as starting material for IPs with the
antibodies indicated above the lanes or with no antibody (No Ab). The
upper panel shows a titration of input material analyzed by PCR with
test primers (T) U6-4U and U6-2L specific for the U6-1 promoter. The
lower panel shows immunoprecipitated material analyzed by PCR with
test primers U6-4U and U6-2L as described above or control primers
(C) U64-1 and U64-120 hybridizing to an inactive U6-4 gene. (B) Ei-
ther naked (N; lane 1) or chromatinized (C; lanes 2 to 7) U6 template
was incubated with hStaf and/or apyrase as indicated above the lanes,
treated with micrococcal nuclease, and then analyzed by linear PCR as
described previously (73). The location of the SPH sequence is indi-
cated. Arrowheads mark the differences in the digestion patterns of
chromatinized and naked DNA. Numbers to the left of the lanes
indicate sizes of DNA markers in nucleotides. (C) hStaf activates U6
transcription from a chromatin template. A U6 template with wild-type
(lanes 1, 2, 5, and 6) or mutated (lanes 3, 4, 7, and 8) SPH motif (SPH
motif TTCCCATGATTCCTTCAT mutated to TTaaaATGATTCCT
TCAT [lowercase italic letters indicate mutations]) was either assem-
bled (lanes 1 to 4) or not assembled (lanes 5 to 8) into chromatin with
(lanes 2, 4, 6, and 8) or without (lanes 1, 3, 5, and 7) hStaf and
incubated with an hStaf-depleted HeLa cell extract for transcription.
The signal corresponding to U6 promoter-directed transcription (U6),
as well as an internal control (IC) corresponding to a radiolabeled
G-less RNA fragment added at the beginning of the transcription
reaction to control for RNA handling, is indicated. Lanes 1 through 4
are from one gel, and lanes 5 through 8 are from another.
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most peptide hits was CHD8, with 23 peptide hits and a 13.3%
sequence coverage in the hStafC analysis, and we therefore
focused on it as a possible hStaf binding partner and transcrip-
tion activator.
CHD8 primary structure. CHD8 belongs to subfamily III
of CHD proteins. As shown in Fig. 3A, it contains two
chromodomains, a helicase domain, three regions conserved
in CHD6 through CHD9, a SANT domain, and two BRK
domains. The peptide hits from our MudPIT results were
matched to an old version of the CHD8 sequence,
XP_370738, which was later replaced with a newer version,
NP_065971. The older version contained an N-terminal 279-
amino-acid extension (Fig. 3B, red) in place of the first two
amino acids (methionine and lysine) of the newer version.
Our data are consistent with a CHD8 protein matching the
older sequence. Indeed, some of the CHD8 peptides iden-
tified by MudPIT were matched to the sequence unique to
the large form, and one peptide spanned the junction of the
large and small forms of CHD8 (Fig. 3B). Moreover, we
raised two antibodies directed against peptides in the N- and
C-terminal regions of CHD8 (Fig. 3B), which both recognize
the same major band greater than 250 kDa in nuclear ex-
tracts (data not shown). Finally, BLAST searches of the
NCBI protein database identified mouse (XP_619244) and
rat (XP_573762) CHD8 homologs, as well as a partial CHD8
sequence from a chimpanzee (XP_509818). These three
proteins contain N-terminal sequences that are 94, 95, and
99% identical, respectively, to the N-terminal extension of
the human protein. These data strongly suggest that the
large form of CHD8, XP_37038, exists in cells and was
pulled down by GST-hStaf. They do not, however, exclude
the possibility that the short form also associates with hStaf.
The long and short forms are likely to arise by alternative
FIG. 2. MudPIT analysis of hStaf-associated proteins. (A) hStaf
constructs used in the GST pull-down experiments. a.a, amino acid.
(B) Proteins associated with full-length hStaf and hStafC or with
hStafC only that were identified in the MudPIT analysis. Proteins
identified only in the hStafC pull-down experiment are marked with
an asterisk. Entries for proteins known or suspected to be involved in
chromatin modification are shaded blue. The proteins are arranged by
the number of peptides identified and then by sequence coverage.
FIG. 3. Structure of human CHD8. (A) Diagram of human CHD8.
(B) Amino acid sequence of CHD8 according to the XP_370738 entry.
The amino acids marked in red are the additional amino acids missing
in the current human CHD8 protein sequence, NP_065971. The un-
derlined sequences correspond to the peptide matches identified by
MudPIT analysis. In some cases, the sequence underlined corresponds
to several peptides of different ionization states or to two or more
adjacent peptides. The two peptide sequences in uppercase letters
were used to produce anti-CHD8 antibodies.
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splicing, because the first two amino acids of the short form
(absent in the long one) are encoded by the end of the second
exon displayed in the University of California—Santa Cruz
human genome viewer. We identified a stretch of genomic
sequence about 150 bp downstream of the second exon that is
able to encode the entire N-terminal unique sequence of the
large form. Thus, the short and long forms may arise by dif-
ferential inclusion of either exon 2 or another exon located
about 150 bp downstream.
The CHD8 protein coimmunoprecipitates with hStaf and is
localized on the U6 and U1 promoters in vivo. To confirm the
interaction between CHD8 and hStaf, we tested whether the
two proteins coimmunoprecipitated. As shown in Fig. 4A,
hStaf was easily detected in anti-CHD8 immunoprecipitates,
and CHD8 was detected, albeit weakly, in anti-hStaf immuno-
precipitates (lanes 3 and 6), suggesting that CHD8 and hStaf
interact inside cells. However, since hStaf is involved in tran-
scription activation of several Pol II and Pol III genes (34, 50),
it was possible that hStaf interacted with CHD8 but did not
recruit CHD8 to the U6 promoter. We therefore tested
whether CHD8 is localized on the U6 promoter by ChIP as
described above. We also tested the Pol II snRNA promoter
U1, as hStaf can also activate Pol II snRNA promoters (35). As
shown in Fig. 4B, CHD8 was detected on the U6-1 promoter
but not on the promoter of the inactive U6-4 gene (compare
lanes 9 and 10). Moreover, both hStaf and CHD8 were de-
tected on the Pol II U1 snRNA promoter, as shown in Fig. 4C
(lanes 9 to 12). The antibody used in the ChIP specifically
recognizes the large isoform of CHD8, indicating that this
isoform resides on the U6 and U1 promoters. This does not
exclude the possibility that the small isoform is also present.
CHD8 interacts specifically with histone H3 methylated at
lysine 4. Chromodomains recognize and interact with methyl-
ated lysine residues of histones (21, 31, 39). In particular, the
double chromodomain of human CHD1 interacts with di- and
trimethylated lysine 4 of histone H3 (13, 59). Since CHD8
contains the double chromodomain characteristic of CHD pro-
teins, we tested whether CHD8 interacts with lysine-methyl-
ated histone H3. Material partially purified by affinity chroma-
tography over a GST-hStaf column, containing CHD8 as well
as human Ino80 (and other hStaf-associated proteins) was
incubated with biotinylated peptides corresponding to the first
21 amino acids of histone H3. First, unmodified, dimethyl-
ated-K4 (K4M2), acetylated-K9 (K9Ac), and phosphorylated-
S10 (S10P) peptides were tested. After incubation with the
partially purified material, the biotinylated peptides were re-
covered with streptavidin beads, and the presence of CHD8
and, as a control, human Ino80 was tested by immunoblotting.
As shown in Fig. 5A, the largest amount of CHD8 was recov-
ered with the H3 K4M2 peptide followed by the unmodified
H3 peptide, whereas little or no detectable CHD8 was recov-
ered with the H3 K9Ac and H3 S10P peptides. In contrast,
human Ino80 bound equally to all peptides, suggesting that the
differential binding of CHD8 is not due to different peptide
amounts. We then compared CHD8 interactions with biotin-
ylated H3 peptides (amino acids 1 to 21 or 21 to 44) dimethyl-
ated at K4, K9, or K36. As shown in Fig. 5B, CHD8 bound
efficiently to dimethylated-K4 peptide and weakly to dimethyl-
ated-K9 and -K36 peptides, whereas hIno80 bound equally
well to all peptides.
It has been shown that different methylation levels at lysines
4 and 9 of histone H3 are enriched in different regions of a
transcribed gene (38, 41, 42, 44) and may thus bear different
information. We therefore tested the affinities of CHD8 for H3
peptides carrying different numbers of methyl groups on the
K4 residue. As shown in Fig. 5C, CHD8, unlike the hIno80
control, bound more efficiently to dimethylated and especially
trimethylated H3K4 peptides than to monomethylated and
unmodified peptides. The strong CHD8 interaction with tri-
methylated H3K4 peptide was not prevented by treatment with
RNase A, suggesting that it is not mediated by an RNA mol-
ecule (Fig. 5D). Thus, CHD8 interacts preferentially with his-
tone H3 di- and trimethylated on lysine 4.
Since CHD8 localizes to the U6-1 promoter and since it
associates with peptides corresponding to the N terminus of
histone H3 di- and trimethylated on lysine 4, we checked
whether histone H3 carrying these modifications is enriched in
the vicinity of the U6 promoter. Indeed, as shown in Fig. 5E,
ChIPs with antibodies specific for histone H3 di- and trimethyl-
ated on lysine 4 revealed the presence of these modified H3
histones in the U6 promoter region. These results suggest that
Pol III genes, like Pol II genes, can be modified by methylation
of histone H3 on lysine 4, and they are consistent with the U6
promoter being a CHD8 target.
FIG. 4. CHD8 interacts with hStaf and is localized on the U6 pro-
moter. T, test primers; C, control primers; Ab, antibody. (A) Co-IP of
hStaf and CHD8. A HeLa cell nuclear extract (NE) was used as the
starting material for nondenaturing IPs with antibodies indicated
above the lanes or, as a control, protein G beads. The immunoprecipi-
tates were fractionated by SDS-PAGE, transferred to a membrane,
and probed by immunoblotting with antibodies directed against hStaf
(left panel) or CHD8 (right panel). The percentages below the lanes
indicate the fractions of the total samples loaded in the lane.
(B) CHD8 is localized on the U6-1 promoter. ChIPs were performed
as described for the lower panel of Fig. 1A, with the antibodies indi-
cated above the lanes. (C) CHD8 and hStaf are localized on the Pol II
snRNA U1 promoter. ChIPs were performed with the antibodies in-
dicated above the lanes as described for the lower panel of Fig. 1A
except that the precipitated material was analyzed by PCR with prim-
ers hybridizing to the human U1 promoter (see Materials and Methods
for the primer sequences).
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CHD8 is involved in U6 transcription. The interaction be-
tween CHD8 and hStaf as well as the localization of CHD8 on
an active, but not an inactive, human U6 promoter suggests
that CHD8 may be involved in U6 transcription in vivo. To
address this possibility, we knocked down CHD8 in an IMR90/
hTert U6 reporter cell line (IMR90-C2.5) containing an inte-
grated hU6/Hae/RA.2 construct derivative in which the human
U6-1 promoter directs the synthesis of unstable transcripts (28;
see Materials and Methods). The reporter line was used be-
cause it is difficult to detect transcriptional changes by mea-
suring the cellular U6 snRNA content. The reasons for this are
not clear but could be due to the existence of different popu-
lations of U6 snRNA (for example, assembled or not assem-
bled with snRNPs) with different stabilities. The reporter cell
line was transfected with two different anti-CHD8 double-
stranded silencing RNA oligonucleotides (small interfering
RNAs [siRNAs]) and CHD8 mRNA and protein levels were
measured with RT-PCR and Western blot analysis, respec-
tively. RNA levels derived from the U6 reporter were tested by
RT-PCR. As shown in Fig. 6A, both CHD8 protein and
mRNA levels went down significantly after anti-CHD8 siRNA
transfection (oligonucleotides C8-1 and C8-2) but not after
control siRNA transfection (oligonucleotide C) (see the three
upper panels). hStaf levels were unaffected (data not shown).
In independent CHD8 knock-down experiments, we observed
decreases in U6 reporter transcription ranging from 4-fold
FIG. 5. CHD8 interacts with histone H3 peptides. NE, nuclear
HeLa cell extract. (A) CHD8 interacts specifically with an unmodified
histone H3 N-terminal peptide and a histone H3 N-terminal peptide
dimethylated at lysine 4. CHD8 partially purified over the GST-hStaf
affinity column was incubated with biotinylated histone H3 peptides
carrying various modifications, as indicated above the lanes. The pro-
tein-peptide complexes were recovered with streptavidin beads, frac-
tionated by SDS-PAGE, transferred to a membrane, and probed by
immunoblotting with an anti-CHD8 antibody as indicated to the right
of the panels. For a control, the membrane was also probed with an
anti-hIno80 antibody as indicated to the right of the panels. (B) CHD8
preferentially interacts with a histone H3 peptide dimethylated at
lysine 4. The experiment was performed as described for panel A but
with the H3 peptides indicated above the lanes. (C) CHD8 preferen-
tially interacts with histone H3 peptides di- and trimethylated at lysine
4. The experiment was performed as described for panel A but with the
H3 peptides indicated above the lanes. In panels A, B, and C, the H3
peptides corresponded to the first 21 amino acids of histone H3 un-
modified (UM), dimethylated at lysine 4 (K4M2), acetylated at lysine
9 (K9Ac), phosphorylated at serine 10 (S10P), dimethylated at lysine 9
(K9M2), monomethylated at lysine 4 (K4M1), trimethylated at lysine
4 (K4M3), or corresponded to amino acids 21 to 44 of histone H3
dimethylated at lysine 36 (K36M2). (D) The interactions between
CHD8 and the H3 K4M3 peptide are not prevented by treatment with
RNase A. The experiment was performed as described for panel A, but
the protein samples were left untreated or treated with water (Mock)
or RNase A before incubation with biotinylated H3 K4M3 peptide.
(E) The U6-1 promoter region contains histone H3 di- and trimethyl-
ated at lysine 4. ChIPs were performed as described for the lower panel
of Fig. 1A. Ab, antibody; T, test primers; C, control primers.
FIG. 6. CHD8 is required for expression of the U6 reporter.
(A) The IMR90-C2.5 reporter cell line was either not transfected (NT)
or transfected with the siRNAs indicated above the lanes. After three
rounds of transfection, the CHD8 and hIno80 contents were analyzed
by immunoblotting (two upper panels) and the CHD8 mRNA, U6
reporter transcript, and -actin mRNA contents were analyzed by
RT-PCR (four lower panels). U6r-a and U6r-b, expression from the
U6 reporter plasmid, experiments a and b, respectively. (B) CHD8 is
involved in transcription of the IRF3 gene. The IRF3 and -actin
mRNA contents were analyzed by RT-PCR. The numbers below the
lanes indicate the intensity of the RT-PCR signal normalized to the
-actin signal. NT, cells not transfected. (C) The relative amount
(nontransfected cells [NT]  100) of U6 reporter transcript or IRF3
mRNA from control oligonucleotide (C)- or C8-2 oligonucleotide-
transfected cells. The averages from six (for U6 reporter) or four (for
IRF3 mRNA) independent RNAi experiments were plotted and the
standard deviations (error bars) are shown. Wilcoxon rank sum tests
were used to test the significance of the RNAi knock-down effect. For
the U6 reporter (n  6), the P value for C8-2-transfected cells in
comparison to nontransfected cells is 0.0022 and the P value for the
control oligonucleotide-transfected cells in comparison to nontrans-
fected cells is 1. For the IRF3 mRNA (n  4), the P value for
C8-2-transfected cells in comparison to nontransfected cells is 0.0286
and the P value for the control oligonucleotide-transfected cells in
comparison to nontransfected cells is 0.31. (D) CHD8 is localized on
the IRF3 promoter. ChIPs were performed as described for the lower
panel of Fig. 1A except that the PCR was performed with test primers
specific for the IRF3 promoter (T) or control (C) primers hybridizing
to an inactive U6-4 gene. Ab, antibody.
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(Fig. 6A, panel U6r-a) to 0.6-fold (panel U6r-b). However,
even though the decrease in the U6 transcript was moderate, it
was significant (n  6, P  0.0022 [Wilcoxon rank sum test];
see the legend to Fig. 6C). Thus, CHD8 contributes to efficient
transcription from the human U6 promoter in vivo. The mod-
est effect of CHD8 knock-down on ongoing U6 transcription is,
perhaps, not unexpected, as CHD8 may be part of an extensive
network of chromatin modifying proteins at the U6 promoter,
which may have partially redundant functions.
CHD8 is involved in IRF3 expression. In addition to regu-
lating transcription of Pol III genes, hStaf has been reported to
regulate the transcription of seven Pol II mRNA genes (34).
We tested mRNA levels for three of them, AKR1A1, IRF3,
and TCP1, after decreasing cellular CHD8 levels by RNAi as
described before. As shown in Fig. 6B, IRF3 mRNA levels
went down after transfection of two different siRNAs directed
against CHD8 (C8-1 and C8-2) but not after transfection of a
control siRNA. The effect was again modest but statistically
significant (n 4, P 0.0286 [Wilcoxon rank sum test]; see the
legend to Fig. 6C) and suggested that CHD8 could be involved
in transcription regulation of the IRF3 gene. We did not ob-
serve, however, a significant reduction in mRNA levels for the
AKR1A1 and TCP1 genes (data not shown), suggesting either
that CHD8 is not involved in transcription of these genes or
that these mRNAs are stable, preventing the detection of sub-
tle changes over a relatively short period of time.
If CHD8 is indeed involved in IRF3 expression, one should
be able to detect it at the IRF3 promoter. We performed a
ChIP with anti-CHD8 and other antibodies and used a primer
set specific for the IRF3 promoter to amplify the immunopre-
cipitated DNA fragments. As shown in Fig. 6D, the ChIP
results indicated the presence of TFIIB, but not the Pol III
transcription factor Brf2, on the IRF3 promoter (lanes labeled
T) but not on the 5 flanking region of the inactive U6-4 gene
(lanes labeled C). Importantly, hStaf as well as CHD8 was also
specifically detected on the IRF3 promoter (lanes 9 to 12). The
CHD8 signal was weak but comparable to that of the positive
TFIIB control (lane 5). These results show that hStaf and
CHD8 reside on a Pol II mRNA promoter.
DISCUSSION
Most chromatin-modifying activities have been studied in
the context of Pol II transcription. Little is known about chro-
matin-modifying activities required for transcription of the few
hundred Pol III genes interspersed in the genome. In particu-
lar, it is not clear whether these activities are dedicated to Pol
III genes. The identification of CHD8 as an hStaf-associated
polypeptide involved in U6 transcription strongly suggests that
Pol III transcription from type 3 promoters involves chromatin
remodeling. Moreover, the observations that the DSEs in type
3 Pol III promoters and in Pol II snRNA promoters are inter-
changeable (17), that CHD8 is localized on both the Pol III U6
and Pol II U1 promoters, and that CHD8 is involved in tran-
scription from the IRF3 mRNA promoter suggest that type 3
Pol III promoters, Pol II snRNA promoters, and Pol II mRNA
promoters share common chromatin-modifying activities.
Thus, the DSE-binding factor hStaf and perhaps Oct-1, which
are both also used by some Pol II mRNA promoters, may
recruit similar chromatin-modifying activities in these three
contexts.
If type 3 Pol III promoters recruit at least some of the
chromatin-modifying activities used by Pol II genes, they may
use different chromatin-remodeling activities than type 1 and 2
Pol III promoters. Indeed, the WICH complex, composed of
the Williams syndrome transcription factor WSTF, SNF2h,
and other factors, was recently shown to associate with the type
1 5S and the mixed type 2 and 3 7SL genes and to be involved
in their transcription, as down-regulation of WSTF by RNAi
resulted in reduced 5S and 7SL transcription (5). However, no
function of WICH in transcription from type 3 promoters
could be demonstrated. How WICH is recruited to 5S rRNA
and 7SL promoters is unknown, but a key player may well turn
out to be the TFIIIC complex. This complex, which is recruited
by type 1 and 2 promoters but not by type 3 promoters, is
essential for chromatin remodeling of the yeast U6 promoter
(which, unlike the human U6 promoter, is a type 2 Pol III
promoter with a TATA box) (56, 57), suggesting that the com-
plex recruits chromatin-remodeling activities. Moreover, two
of the human TFIIIC subunits display histone acetyltransferase
activity (18, 26). Thus, TFIIIC may be central to chromatin
modification at type 1 and 2 Pol III promoters, both modifying
histone tails and recruiting chromatin-remodeling activities.
The mechanism by which hStaf and CHD8 activate tran-
scription from the U6 promoter and how the action of hStaf
combines with that of Oct-1 remain to be elucidated. In pre-
vious experiments, we showed that the Oct-1 POU domain
could activate U6 transcription from a chromatin template
when added during chromatin assembly (78). hStaf is capable
of activating U6 transcription even when added after chroma-
tin assembly, suggesting that it might bind to the U6 promoter
before Oct-1. Its interaction with CHD8 suggests that the
mechanism by which it activates U6 transcription involves re-
cruitment of CHD8, which in turn leads to chromatin remod-
eling. However, it is also possible that CHD8 binds DNA
before hStaf. Indeed, we showed that, like CHD1, CHD8 binds
preferentially to histone H3 carrying a di- or trimethyl group at
lysine 4 and that the U6 promoter region is enriched in histone
H3 carrying these modifications. It is conceivable that in vivo,
these modifications occur before CHD8 binding and then al-
low binding of CHD8 through contacts with lysine 4-methyl-
ated histone H3 and perhaps through direct contacts with the
DNA through the CHD8 putative C-terminal DNA binding
domain. DNA-bound CHD8 could then help recruit hStaf to
its DNA binding site by protein-protein interaction.
The recent discovery that CHD8 associates with CTCF (19)
together with our observation that CHD8 can be localized
around the U6 promoter region open the possibility that CTCF
is bound to insulator sites at or close to the U6 promoter. The
U6-1 gene resides in a relatively barren region in the human
genome, with very few expressed sequence tags encoded in the
upstream 215 kb (http://genome.ucsc.edu/cgi-bin/hgGateway).
In the downstream region, the first known gene is located 5 kb
away and corresponds to the human homolog of mouse Corl1,
a transcription corepressor expressed only in the brain and
testis (32). The U6-1 gene may, therefore, require an active
insulator to separate itself from its probably largely transcrip-
tion-silent environment. Although no exact matches were iden-
tified, several sequences diverging from the human and mouse
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-globin and H19 CTCF binding sites (12, 20) at only a few
positions can be found around the U6-1 gene.
Our analysis of hStaf-associated proteins has revealed sev-
eral proteins known, or likely, to be involved in chromatin
modification. For example, HCF-1 is a heterodimeric protein
generated from its 2,035-amino-acid precursor by site-specific
proteolysis, whose N-terminal subunit associates with the Sin3
histone deacetylase and the Set1/Ash2 histone methyltrans-
ferase complexes (75). It might bring the histone methyltrans-
ferases needed to give rise to the di- and trimethylated histone
H3 present around the U6 promoter. Brd2 and Brd3 are bro-
modomain proteins known to interact with acetylated histones
and, at least in the case of Brd2, to activate transcription (60).
As well, hIno80, nuclear factor related to kappa B binding
protein, and RUVB-like 1 protein are members of the hIno80
complex (22), whose yeast counterpart is involved in transcrip-
tion activation as well as in other processes, such as DNA
repair (33, 54, 70). Although we cannot exclude the possibility
that these factors are involved only in Pol II transcription of
mRNA genes activated by hStaf, they are all potential chro-
matin-modifying factors involved in Pol III transcription from
the U6 promoter.
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